Developer docs
API playgroundTry for free, no card

Search company profiles

Rhythm Metabolic

Full company profile

uuid000donf

Namestring
Rhythm Metabolic
Legal namestring
Rhythm Pharmaceuticals, Inc.
Websiteurl
rhythmtx.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the development and commercialization of precision medicines for rare neuroendocrine diseases. Its therapeutic platform targets the melanocortin-4 receptor (MC4R) pathway to treat hyperphagia (pathological, insatiable hunger) and severe obesity caused by rare genetic variants or hypothalamic injury, including Bardet-Biedl syndrome, POMC/PCSK1/LEPR deficiency obesities, acquired hypothalamic obesity, and Prader-Willi syndrome. The company's lead product is IMCIVREE (setmelanotide), a first-in-class MC4R agonist injection approved by the FDA in 2020 for POMC and LEPR deficiency obesity, expanded to BBS in 2022, and authorized by the European Commission; a further label expansion was approved in 2026.

The commercial product is paired with a deep late-stage pipeline that diversifies modality and frequency of administration: Bivamelagon (LB54640), an oral, non-hyperpigmenting MC4R-specific agonist acquired from LG Chem Life Sciences in 2024 (Phase 2 SIGNAL trial in acquired hypothalamic obesity); and RM-718, a weekly MC4R-specific agonist also designed to avoid hyperpigmentation, in Phase 2. Underpinning this pipeline is a proprietary DNA sequencing data platform containing approximately 80,000 de-identified genetic samples from individuals with severe obesity, used in genetic epidemiological analyses to identify rare MC4R pathway variants.

Rhythm operates as a commercial rare disease biopharma with field sales and patient support infrastructure. IMCIVREE is distributed through specialty pharmacy channels and HUB services (including the Rhythm InTune patient support program), reimbursed via payer/negotiated pathways for confirmed genetic diagnoses. The company generates essentially all revenue from pharmaceutical product sales (IMCIVREE) in the US and Europe, operates a wholly-owned Dutch subsidiary and a UK subsidiary for European commercialization, and is publicly traded on Nasdaq (ticker RYTM) since a 2017 IPO with cumulative financing exceeding $1 billion led by CFO Hunter Smith. The company employs 400+ staff across North America and Europe and is headquartered at 222 Berkeley Street, Boston, Massachusetts.

Short descriptiontext

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company developing precision MC4R pathway medicines (lead: IMCIVREE/setmelanotide) for rare neuroendocrine diseases including Bardet-Biedl syndrome and POMC/PCSK1/LEPR deficiency obesity, supported by an injectable, oral and weekly pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, precision medicine development, MC4R receptor agonists, genetic obesity treatments, orphan drug therapy
Industry2 codes
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Rare Disease Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales (IMCIVREE)
TypeOne Time License
Description

Rhythm generates revenue through the commercial sale of its FDA-approved drug IMCIVREE (setmelanotide) injection, prescribed to patients with rare MC4R pathway obesity conditions. Revenue is derived from prescription volumes in the US and Europe following regulatory approvals.

rhythmtx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Pricing details1 tier
1IMCIVREE (setmelanotide) is available as an FDA-approved prescription injection for eligible patients with confirmed genetic diagnoses.
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed on corporate website. Payer/reimbursement pathways apply for eligible patients with rare MC4R pathway diseases.

rhythmtx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1IMCIVREE
Description

FDA-approved setmelanotide injection for rare obesity conditions

rhythmtx.com
+4 more records
Core offering1 text field

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and sells precision medicines for rare neuroendocrine diseases. Its core commercial product is IMCIVREE (setmelanotide), an FDA-approved MC4R receptor agonist injection for chronic weight management in patients with monogenic or syndromic obesity due to POMC, PCSK1, or LEPR deficiency and Bardet-Biedl syndrome. The company also advances a pipeline of oral and weekly MC4R agonists (Bivamelagon, RM-718) and operates a proprietary DNA sequencing data platform supporting rare obesity research.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 3 TRANSCEND trial completed for congenital hypothalamic obesity; Phase 3 EMANATE ongoing for POMC/LEPR insufficiency and SRC1/SH2B1 deficiency obesity.
+3 more records
Product overview1 text field

Rhythm Pharmaceuticals is a global biopharmaceutical company with a focused portfolio of precision medicines for rare neuroendocrine diseases. The core product is IMCIVREE (setmelanotide), an FDA-approved injection for chronic weight management in patients with rare obesity caused by MC4R pathway impairments. The pipeline includes Bivamelagon (LB54640), an oral MC4R agonist in Phase 2 for acquired hypothalamic obesity, and RM-718, a weekly MC4R agonist also in Phase 2. Supporting offerings include Rhythm InTune patient support program and a proprietary DNA sequencing data platform of approximately 80,000 genetic samples for research.

Product and service3 records
1IMCIVREE (setmelanotide) injection
CategoryApproved Pharmaceutical Product
Description

FDA-approved MC4R agonist precision medicine injection for chronic weight management in patients 6 years and older with monogenic or syndromic obesity due to POMC, PCSK1, or LEPR deficiency, or Bardet-Biedl syndrome (BBS). Prescribed by endocrinologists, geneticists, and obesity specialists and dispensed via specialty pharmacy channels.

2Bivamelagon (LB54640)
CategoryInvestigational Pharmaceutical Product (Pipeline)
Description

Investigational oral, MC4R-specific agonist designed not to cause hyperpigmentation. Being evaluated in Phase 2 as a potential therapy for acquired hypothalamic obesity, intended to broaden treatment options beyond injectable setmelanotide.

3RM-718
CategoryInvestigational Pharmaceutical Product (Pipeline)
Description

Investigational weekly MC4R-specific agonist designed not to cause hyperpigmentation, currently in Phase 2 development for rare MC4R pathway obesity indications.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1LG Chem Life Sciences
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-01-01
Description

In 2024, Rhythm acquired the oral MC4R agonist LB54640 (now called Bivamelagon) from LG Chem Life Sciences. This acquisition expanded Rhythm's pipeline with an investigational oral therapy that does not cause hyperpigmentation, complementing the existing setmelanotide franchise.

rhythmtx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Rhythm acquired Xinvento in 2023, expanding its pipeline and capabilities in rare neuroendocrine diseases. The acquisition contributed to Rhythm's ongoing expansion of treatment options for patients with rare MC4R pathway diseases.

3Physician-scientist community / Investigator-initiated research partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Rhythm supports investigator-initiated studies focused on neuroendocrine diseases including natural history, genotype-phenotype correlations, energy expenditure, hyperphagia, and real-world experience with setmelanotide. Studies are scoped to rare MC4R pathway diseases; general obesity or non-rare disease studies are outside scope.

rhythmtx.com
Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Soleno Therapeutics is developing DCCR (diazoxide choline) for Prader-Willi syndrome, directly overlapping Rhythm's PWS Phase 2 setmelanotide program and competing for the same hyperphagia/obesity patient population. It is the most direct clinical competitor in Rhythm's franchise expansion path.

TypeDirect peer
Description

Crinetics focuses on rare endocrine diseases with an oral peptide platform (e.g., paltusotine for acromegaly). Direct overlap with Rhythm's rare-neuroendocrine / MC4R scientific area, plus shared business model of developing precision medicines for small endocrine patient populations.

TypeEmerging player
Description

Aardvark is developing oral small molecules (e.g., ARD-101) targeting hunger and metabolic signaling pathways, including rare genetic obesity indications. Directly comparable in mechanism-goal (modulating hunger/weight) and rare-disease positioning.

TypeBroad incumbent
Description

BioMarin is a large rare-disease commercial biopharma operating globally with multiple approved enzyme replacement and gene therapy products. Comparable in rare-disease commercialization model, regulatory expertise, and patient-finding infrastructure underpinning Rhythm's specialty-pharmacy/HUB go-to-market.

TypeBroad incumbent
Description

Ultragenyx commercializes multiple rare-disease enzyme replacement and gene therapy products globally. Shares Rhythm's model of identifying tiny patient populations for inherited metabolic disorders and operating specialty distribution plus field sales infrastructure.

TypeEmerging player
Description

Krystal Biotech is a commercial-stage rare-disease biotech with approved Vyjuvek, distributed through specialty channels. Head of North America Jennifer Lee came from Krystal; the company shares the small-team, focused-portfolio, rare-disease launch playbook Rhythm employs.

TypeBroad incumbent
Description

Alexion pioneered ultra-rare-disease specialty pharma with Soliris/Strensiq and was an explicit career background of multiple Rhythm executives (and Chief Regulatory Officer Alicia Fiscus). Benchmark for the rare-disease commercial model Rhythm follows.

TypeBroad incumbent
Description

Lilly leads the broader obesity space with Zepbound (tirzepatide) and an extensive obesity pipeline including MC4R-pathway-adjacent programs. The dominant commercial threat and benchmark for obesity therapeutic economics that Rhythm's next-gen pipeline (oral Bivamelagon, weekly RM-718) seeks to compete with on tolerability/dosing.

TypeBroad incumbent
Description

Novo Nordisk sets the standard in obesity therapeutics with Wegovy/Saxenda and an expanding pipeline (CagriSema). Directly comparable in disease area (obesity) but operates at vastly larger scale in common obesity; defines the reimbursement and competitive backdrop against which Rhythm's rare-genetic franchise must justify pricing.

TypeEmerging player
Description

Viking Therapeutics is a clinical-stage biotech focused on obesity and metabolic disease with an oral and injectable pipeline. Comparable in therapeutic area and stage-gated development model; represents emerging competition in metabolic disease that could overlap with Rhythm's next-gen obesity ambitions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rhythm Metabolic

Rare Disease Biopharmaceuticalsrhythmtx.com

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company developing precision MC4R pathway medicines (lead: IMCIVREE/setmelanotide) for rare neuroendocrine diseases including Bardet-Biedl syndrome and POMC/PCSK1/LEPR deficiency obesity, supported by an injectable, oral and weekly pipeline.

What Rhythm Metabolic does

Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the development and commercialization of precision medicines for rare neuroendocrine diseases. Its therapeutic platform targets the melanocortin-4 receptor (MC4R) pathway to treat hyperphagia (pathological, insatiable hunger) and severe obesity caused by rare genetic variants or hypothalamic injury, including Bardet-Biedl syndrome, POMC/PCSK1/LEPR deficiency obesities, acquired hypothalamic obesity, and Prader-Willi syndrome. The company's lead product is IMCIVREE (setmelanotide), a first-in-class MC4R agonist injection approved by the FDA in 2020 for POMC and LEPR deficiency obesity, expanded to BBS in 2022, and authorized by the European Commission; a further label expansion was approved in 2026.

The commercial product is paired with a deep late-stage pipeline that diversifies modality and frequency of administration: Bivamelagon (LB54640), an oral, non-hyperpigmenting MC4R-specific agonist acquired from LG Chem Life Sciences in 2024 (Phase 2 SIGNAL trial in acquired hypothalamic obesity); and RM-718, a weekly MC4R-specific agonist also designed to avoid hyperpigmentation, in Phase 2. Underpinning this pipeline is a proprietary DNA sequencing data platform containing approximately 80,000 de-identified genetic samples from individuals with severe obesity, used in genetic epidemiological analyses to identify rare MC4R pathway variants.

Rhythm operates as a commercial rare disease biopharma with field sales and patient support infrastructure. IMCIVREE is distributed through specialty pharmacy channels and HUB services (including the Rhythm InTune patient support program), reimbursed via payer/negotiated pathways for confirmed genetic diagnoses. The company generates essentially all revenue from pharmaceutical product sales (IMCIVREE) in the US and Europe, operates a wholly-owned Dutch subsidiary and a UK subsidiary for European commercialization, and is publicly traded on Nasdaq (ticker RYTM) since a 2017 IPO with cumulative financing exceeding $1 billion led by CFO Hunter Smith. The company employs 400+ staff across North America and Europe and is headquartered at 222 Berkeley Street, Boston, Massachusetts.

Rhythm Metabolic firmographics

Firmographics
Name
Rhythm Metabolic
Legal name
Rhythm Pharmaceuticals, Inc.
Website
https://rhythmtx.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
251–500 employees
Short description
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company developing precision MC4R pathway medicines (lead: IMCIVREE/setmelanotide) for rare neuroendocrine diseases including Bardet-Biedl syndrome and POMC/PCSK1/LEPR deficiency obesity, supported by an injectable, oral and weekly pipeline.
Ownership category
akta.pro rank

Rhythm Metabolic industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Precision medicine development
  • MC4R receptor agonists
  • Genetic obesity treatments
  • Orphan drug therapy

Where Rhythm Metabolic is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Rhythm Metabolic business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Pharmaceutical product sales (IMCIVREE): Rhythm generates revenue through the commercial sale of its FDA-approved drug IMCIVREE (setmelanotide) injection, prescribed to patients with rare MC4R pathway obesity conditions. Revenue is derived from prescription volumes in the US and Europe following regulatory approvals.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractIMCIVREE (setmelanotide) is available as an FDA-approved prescription injection for eligible patients with confirmed genetic diagnoses.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Rhythm Metabolic product offering

Product offering

Core offering

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and sells precision medicines for rare neuroendocrine diseases. Its core commercial product is IMCIVREE (setmelanotide), an FDA-approved MC4R receptor agonist injection for chronic weight management in patients with monogenic or syndromic obesity due to POMC, PCSK1, or LEPR deficiency and Bardet-Biedl syndrome. The company also advances a pipeline of oral and weekly MC4R agonists (Bivamelagon, RM-718) and operates a proprietary DNA sequencing data platform supporting rare obesity research.

Product overview

Rhythm Pharmaceuticals is a global biopharmaceutical company with a focused portfolio of precision medicines for rare neuroendocrine diseases. The core product is IMCIVREE (setmelanotide), an FDA-approved injection for chronic weight management in patients with rare obesity caused by MC4R pathway impairments. The pipeline includes Bivamelagon (LB54640), an oral MC4R agonist in Phase 2 for acquired hypothalamic obesity, and RM-718, a weekly MC4R agonist also in Phase 2. Supporting offerings include Rhythm InTune patient support program and a proprietary DNA sequencing data platform of approximately 80,000 genetic samples for research.

Differentiator

Problem solved

Functional benefit

Brands

  • IMCIVREE: FDA-approved setmelanotide injection for rare obesity conditions
  • Rhythm InTune
  • LEAD for Rare Obesity
  • GOLD Academy
  • Uncovering Rare Obesity

Products and services

  • IMCIVREE (setmelanotide) injection FDA-approved MC4R agonist precision medicine injection for chronic weight management in patients 6 years and older with monogenic or syndromic obesity due to POMC, PCSK1, or LEPR deficiency, or Bardet-Biedl syndrome (BBS). Prescribed by endocrinologists, geneticists, and obesity specialists and dispensed via specialty pharmacy channels.
  • Bivamelagon (LB54640) Investigational oral, MC4R-specific agonist designed not to cause hyperpigmentation. Being evaluated in Phase 2 as a potential therapy for acquired hypothalamic obesity, intended to broaden treatment options beyond injectable setmelanotide.
  • RM-718 Investigational weekly MC4R-specific agonist designed not to cause hyperpigmentation, currently in Phase 2 development for rare MC4R pathway obesity indications.

Quantifiable outcome

  • Phase 3 TRANSCEND trial completed for congenital hypothalamic obesity; Phase 3 EMANATE ongoing for POMC/LEPR insufficiency and SRC1/SH2B1 deficiency obesity.
  • +3 more outcomes

Companies that use Rhythm Metabolic

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Rhythm Metabolic technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Rhythm Metabolic partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • LG Chem Life SciencescoreOEM/ Whitelabel/ Licensing Partner · 1 January 2024In 2024, Rhythm acquired the oral MC4R agonist LB54640 (now called Bivamelagon) from LG Chem Life Sciences. This acquisition expanded Rhythm's pipeline with an investigational oral therapy that does not cause hyperpigmentation, complementing the existing setmelanotide franchise.
  • XinventocoreStrategic or Co-development Partner · 1 January 2023Rhythm acquired Xinvento in 2023, expanding its pipeline and capabilities in rare neuroendocrine diseases. The acquisition contributed to Rhythm's ongoing expansion of treatment options for patients with rare MC4R pathway diseases.
  • Physician-scientist community / Investigator-initiated research partnersminorStrategic or Co-development PartnerRhythm supports investigator-initiated studies focused on neuroendocrine diseases including natural history, genotype-phenotype correlations, energy expenditure, hyperphagia, and real-world experience with setmelanotide. Studies are scoped to rare MC4R pathway diseases; general obesity or non-rare disease studies are outside scope.

Scale indicators5 records

Recent moves11 records

Expansion highlights8 records

Rhythm Metabolic competitors and assessment

Company assessment

Direct peers

  • Soleno Therapeutics: Soleno Therapeutics is developing DCCR (diazoxide choline) for Prader-Willi syndrome, directly overlapping Rhythm's PWS Phase 2 setmelanotide program and competing for the same hyperphagia/obesity patient population. It is the most direct clinical competitor in Rhythm's franchise expansion path.
  • Crinetics Pharmaceuticals: Crinetics focuses on rare endocrine diseases with an oral peptide platform (e.g., paltusotine for acromegaly). Direct overlap with Rhythm's rare-neuroendocrine / MC4R scientific area, plus shared business model of developing precision medicines for small endocrine patient populations.

Emerging players

  • Aardvark Therapeutics: Aardvark is developing oral small molecules (e.g., ARD-101) targeting hunger and metabolic signaling pathways, including rare genetic obesity indications. Directly comparable in mechanism-goal (modulating hunger/weight) and rare-disease positioning.
  • Krystal Biotech: Krystal Biotech is a commercial-stage rare-disease biotech with approved Vyjuvek, distributed through specialty channels. Head of North America Jennifer Lee came from Krystal; the company shares the small-team, focused-portfolio, rare-disease launch playbook Rhythm employs.
  • Viking Therapeutics: Viking Therapeutics is a clinical-stage biotech focused on obesity and metabolic disease with an oral and injectable pipeline. Comparable in therapeutic area and stage-gated development model; represents emerging competition in metabolic disease that could overlap with Rhythm's next-gen obesity ambitions.

Broad incumbents

  • BioMarin Pharmaceutical: BioMarin is a large rare-disease commercial biopharma operating globally with multiple approved enzyme replacement and gene therapy products. Comparable in rare-disease commercialization model, regulatory expertise, and patient-finding infrastructure underpinning Rhythm's specialty-pharmacy/HUB go-to-market.
  • Ultragenyx Pharmaceutical: Ultragenyx commercializes multiple rare-disease enzyme replacement and gene therapy products globally. Shares Rhythm's model of identifying tiny patient populations for inherited metabolic disorders and operating specialty distribution plus field sales infrastructure.
  • Alexion (AstraZeneca Rare Disease): Alexion pioneered ultra-rare-disease specialty pharma with Soliris/Strensiq and was an explicit career background of multiple Rhythm executives (and Chief Regulatory Officer Alicia Fiscus). Benchmark for the rare-disease commercial model Rhythm follows.
  • Eli Lilly: Lilly leads the broader obesity space with Zepbound (tirzepatide) and an extensive obesity pipeline including MC4R-pathway-adjacent programs. The dominant commercial threat and benchmark for obesity therapeutic economics that Rhythm's next-gen pipeline (oral Bivamelagon, weekly RM-718) seeks to compete with on tolerability/dosing.
  • Novo Nordisk: Novo Nordisk sets the standard in obesity therapeutics with Wegovy/Saxenda and an expanding pipeline (CagriSema). Directly comparable in disease area (obesity) but operates at vastly larger scale in common obesity; defines the reimbursement and competitive backdrop against which Rhythm's rare-genetic franchise must justify pricing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Rhythm Metabolic social profiles

Digital presence

Rhythm Metabolic compliance and trust

Trust signal

Compliance1 record

Rhythm Metabolic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rhythm Metabolic leadership team

Management profile

Number of profiles

Profiles16 records

Rhythm Metabolic subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Rhythm Metabolic funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rhythm Metabolic M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rhythm Metabolic

What does Rhythm Metabolic do?

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and sells precision medicines for rare neuroendocrine diseases. Its core commercial product is IMCIVREE (setmelanotide), an FDA-approved MC4R receptor agonist injection for chronic weight management in patients with monogenic or syndromic obesity due to POMC, PCSK1, or LEPR deficiency and Bardet-Biedl syndrome. The company also advances a pipeline of oral and weekly MC4R agonists (Bivamelagon, RM-718) and operates a proprietary DNA sequencing data platform supporting rare obesity research.

Is Rhythm Metabolic a public or private company?

Rhythm Metabolic is a public company. It is classified as public and is currently operating.

When was Rhythm Metabolic founded?

Rhythm Metabolic was founded in 2008. It employs 251 to 500 people.

Where is Rhythm Metabolic based?

Rhythm Metabolic is headquartered in Boston, United States, in the North America region.

How does Rhythm Metabolic make money?

One revenue line is on record: pharmaceutical product sales (IMCIVREE).

Who are Rhythm Metabolic's main competitors?

Direct peers on record are Soleno Therapeutics and Crinetics Pharmaceuticals. Emerging players are Aardvark Therapeutics, Krystal Biotech and Viking Therapeutics. Broad incumbents are BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Alexion (AstraZeneca Rare Disease), Eli Lilly and Novo Nordisk.

Does Rhythm Metabolic have an API?

No public API is recorded for Rhythm Metabolic.

What industry is Rhythm Metabolic in?

Rhythm Metabolic's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals